BOSTON – "STRIVE establishes calcitonin gene receptor peptide (CGRP) receptor blockade as the first ever mechanism-specific, migraine targeted preventive treatment approach," Peter Goadsby told his audience at the 2017 annual meeting of the American Academy of Neurology.